TNFSF11 and postmenopausal osteoporosis: The importance of RANKL in the pathogenesis of estrogen-deficiency induced bone loss has been translated into therapeutic use of a humanized monoclonal antibody against RANKL, denosumab, for the treatment of postmenopausal osteoporosis (Zhang et al., 2020).